Research and Markets (http://www.researchandmarkets.com/research/g85p9p/sicklecell) has announced the addition of the "Sickle-cell Anemia Therapeutics Market in the US 2015-2019" report to their offering.
The Sickle-cell Anemia Therapeutics market in the US to grow at a CAGR of 17.10 percent over the period 2014-2019.
Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.
Increasing focus on adult patients is one key trend in this market, which is anticipated to provide better healthcare services to adult patients and improve their QoL.
According to the report, a high degree of unmet medical needs in terms of safe, efficacious, and epilepsy-modifying treatments is one of the major drivers of this market. Any drug that can cater to these demands is expected to drive the market during the forecast period of 2014-2019. .
Further, the report states that the side effects associated with the current therapies are one of the major challenges faced by the market. The more side effects associated with a therapy, the lesser the compliance of patients, which consequently decreases the revenue generation of drugs in the market.
Key Topics Covered:
- Executive Summary
- List of Abbreviations
- Scope of the Report
- Market Research Methodology
- Disease Overview
- Introduction
- Market Landscape
- Buying Criteria
- Market Growth Drivers
- Drivers and their Impact
- Market Challenges
- Impact of Drivers and Challenges
- Market Trends
- Trends and their Impact
- Vendor Landscape
- Future Prominent Vendors
- Key Vendor Analysis
For more information visit http://www.researchandmarkets.com/research/g85p9p/sicklecell
